Barely Significant
← all excerpts

Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.

Breast Cancer · 2024 · PMC11341741 · PMID 38869771

Europe PMCDOI
1
hedged sentence
0.1254
closest p · 2.5× alpha
0.1254
boldest claim

The sentences

did not reach statistical significancep = 0.1254not close (p > 0.1)
A weak association of RB1 alterations with response was observed, although this did not reach statistical significance ( p = 0.1254).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.